Home / Market News / $SNN
benzinga Corporate Catalyst Impact 65/100 ● positive

Smith+Nephew Receives 510(k) Clearance From FDA And Completes First Surgical Cases With LANDMARK Total Knee System

Sep 22, 2026, 12:04 PM UTC · Primary ticker $SNN

Smith+Nephew announced it received FDA 510(k) clearance for its LANDMARK Total Knee System and has completed the first surgical cases. This new knee replacement solution is designed to replicate healthy knee anatomy and natural motion, leveraging the CORI KNEE Handheld Robotics Arthroplasty system, and is suitable for both hospital and ambulatory surgery center environments.

Smith+Nephew's announcement of FDA 510(k) clearance and the completion of initial surgical cases for its LANDMARK Total Knee System is a positive development. This signifies a new product launch in the competitive orthopedic market, potentially expanding SNN's market share and revenue streams in total knee arthroplasty. The system's design, focusing on natural knee motion and leveraging handheld robotics, addresses evolving surgeon and patient demands for more personalized solutions, offering a competitive edge. In the short term, this could lead to increased investor confidence and a modest stock price bump. Long-term, successful adoption and positive patient outcomes will be crucial for sustained growth and market penetration, posing an opportunity for traders to monitor sales figures and adoption rates.

$SNN positive New product launch and FDA clearance
Source: benzinga
Join the waitlist for full signal validation →

Not financial advice. AI-generated analysis for informational purposes only.